Two Small Molecules Show Promise as Broad-Spectrum Coronavirus Inhibitors in Laboratory Study
Researchers found that sennoside A and ceftazidime, two small molecules, can inhibit RNA binding in the nucleocapsid proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV in laboratory experiments. The nucleocapsid protein is highly conserved across coronaviruses and essential for viral replication, making it a potential drug target. The findings suggest these compounds could form the basis for pan-coronavirus antiviral therapies, though further development and clinical testing would be needed.
A preprint study published on bioRxiv reports that sennoside A and ceftazidime inhibit nucleocapsid RNA binding across three major human coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. The researchers purified recombinant nucleocapsid (N) proteins from all three viruses and used electrophoretic mobility shift assays and fluorescence polarization to demonstrate that both compounds significantly reduced RNA binding capacity. Molecular docking analyses indicated that both inhibitors target the RNA-binding pocket of the N-terminal domain through a conserved mechanism. The study builds on earlier work identifying these compounds and reveals that key residues involved in inhibitor binding are conserved across betacoronaviruses, suggesting a shared vulnerability that could be exploited therapeutically. The authors propose these findings highlight the potential for developing broad-spectrum antiviral strategies targeting the nucleocapsid protein.
What's missing
This is a preprint study that has not undergone peer review. The research is limited to in vitro laboratory experiments using purified proteins and does not include cell culture or animal studies demonstrating antiviral efficacy in living systems. Clinical translation and safety profiles remain unknown. The study does not address whether these compounds can cross cellular membranes or achieve therapeutic concentrations in infected organisms.
What different sources said
- bioRxivCenter
Sennoside A and Ceftazidime Inhibit Nucleocapsid RNA BindingAcross SARS-CoV-2, SARS-CoV, and MERS-CoV
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.